WO2022204125A1 - Formes polymorphes de n-(trans-4-hydroxycyclohexyl)-6-phénylhexanamide - Google Patents

Formes polymorphes de n-(trans-4-hydroxycyclohexyl)-6-phénylhexanamide Download PDF

Info

Publication number
WO2022204125A1
WO2022204125A1 PCT/US2022/021321 US2022021321W WO2022204125A1 WO 2022204125 A1 WO2022204125 A1 WO 2022204125A1 US 2022021321 W US2022021321 W US 2022021321W WO 2022204125 A1 WO2022204125 A1 WO 2022204125A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline polymorph
polymorph
ray powder
powder diffraction
radiation
Prior art date
Application number
PCT/US2022/021321
Other languages
English (en)
Inventor
Gerald W. Dorn
Original Assignee
Mitochondria Emotion, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitochondria Emotion, Inc. filed Critical Mitochondria Emotion, Inc.
Publication of WO2022204125A1 publication Critical patent/WO2022204125A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • Mitochondrial dysfunction may contribute to various types of neurodegenerative diseases.
  • Defective mitochondrial fusion or fission may be especially problematic in this regard, especially when imbalanced fusion and fission lead to mitochondrial fragmentation.
  • ALS amyotrophic lateral sclerosis
  • Huntington Huntington
  • Mitochondrial fusion is initiated by outer mitochondrial membrane-embedded mitofusin (MFN) proteins whose extra-organelle domains extend across cytosolic space to interact with counterparts on neighboring mitochondria.
  • MFN mitofusin
  • the physically linked organelles create oligomers of varying sizes.
  • Mitofusins subsequently induce outer mitochondrial membrane fusion mediated by catalytic GTPase.
  • Aberrant mitofusin activity is believed to be a primary contributor to mitochondrial-based neurodegenerative diseases. For these reasons, mitofusins are attractive targets for drug discovery.
  • the present disclosure provides a crystalline polymorph of a compound represented by the structure
  • the present disclosure provides a method of preparing a compound described herein.
  • the present disclosure features a pharmaceutical composition comprising any compound described herein and a pharmaceutically acceptable excipient.
  • the present disclosure features a method of treating diseases, disorders, or conditions, comprising administering to a subject in need thereof any compound described herein in a pharmaceutical composition.
  • the present disclosure features any compound described herein in a pharmaceutical composition for use for treating diseases, disorders, or conditions, comprising administering to a subject in need thereof.
  • the present disclosure features use of any compound described herein in a pharmaceutical composition in the manufacture of a medicament for treating diseases, disorders, or conditions, composing administering to a subject in need thereof.
  • the present disclosure features a method of activating mitofusin in a subject, comprising administering the compound or the pharmaceutical composition of any one of the preceding claims.
  • the present disclosure features any compound described herein in a pharmaceutical composition for use in activating mitofusin in a subject.
  • the present disclosure features use of the any compound described herein in a pharmaceutical composition in the manufacture of a medicament for activating mitofusin in a subject.
  • FIG. 1 shows an illustrative x-ray powder diffraction pattern of as-produced N -(trans- 4-hydroxycyclohexyl)-5-phenylpentanamide (Polymorph 1).
  • FIG. 2 shows an illustrative polarized light microscopy image of as-produced N -(trans- 4-hydroxycyclohexyl)-5-phenylpentanamide (Polymorph 1).
  • FIG. 3 shows an illustrative x-ray powder diffraction pattern of Polymorph 2 of N- (trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 4 shows an illustrative polarized light microscopy image of Polymorph 2 of N- (trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 5 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 2 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide.
  • FIG. 6 shows an illustrative x-ray powder diffraction pattern of Polymorph 3 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 7 shows an illustrative polarized light microscopy image of Polymorph 3 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 8 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 3 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide.
  • FIG. 9 shows an illustrative x-ray powder diffraction pattern of Polymorph 4 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 10 shows an illustrative polarized light microscopy image of Polymorph 4 ofN-(trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 11 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 4 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide.
  • FIG. 12 shows an illustrative x-ray powder diffraction pattern of Polymorph 5 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 13 shows an illustrative polarized light microscopy image of Polymorph 5 of N-(trans-4-hydroxycyclohexy-5- phenylpentanamide
  • FIG. 14 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 5 of (trans-4-hydroxycyclohexy-5- phenylpentanamide.
  • FIG. 15 shows an overlay plot of the x-ray powder diffraction patterns of Polymorphs
  • U.S. Patent Application Publication 2020/0345669 describes various N-(cycloalkyl or heterocycloalkyl) 6- phenylhexanamide compounds or structural variants thereof capable of activating mitofusins. 4-Hydroxycyclohexyl is a particularly effective substituted cycloalkyl in such mitofusin activators.
  • U.S. Patent Application Publication 2020/0345668 describes stereoisomeric N-(4- hydroxycyclohexyl)-6-phenylhexanamide compounds or structural variants thereof that are particularly effective for promoting mitofusin activation. N-(trans-4-hydroxycyclohexy- 6 - phenylhexanamide is the active stereoisomer, whereas the corresponding cis-stereoisomer is inactive toward promoting mitofusin activation.
  • the present disclosure generally relates to mitofusin activation, and more specifically, compositions comprising a crystalline polymorph of N-(trans-4-hydroxycyclohexy- 6 - phenylhexanamide.
  • N-(cycloalkyl or heterocycloalkyl)-6-phenylhexanamide compounds are potent mitofusin activators.
  • N-(trans-4-hydroxycyclohexy- 6 - phenylhexanamide (Formula 1) is an example of a particularly potent mitofusin activator.
  • N-(trans-4-hydroxycyclohexy- 6 -phenylhexanamide is a mitofusin activator may exist as at least five different crystalline polymorphs.
  • the polymorphs may be anhydrates.
  • a crystalline polymorph formed above a phase-transition temperature of about 125°C may be characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 18.43° 2 ⁇ , as measured using Cu K ⁇ radiation.
  • a crystalline polymorph formed below a phase transition temperature of about 40°C may be characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 18.57° 2 ⁇ , as measured using Cu K ⁇ radiation.
  • Pharmaceutical compositions may be prepared from the polymorphs.
  • N-(trans-4-hydroxycyclohexy- 6 -phenylhexan aammiiddee may be obtained as a crystalline polymorph representing the most stable form produced above about 125°C.
  • This polymorph is characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 18.43° 2 ⁇ , as measured using Cu K ⁇ radiation.
  • this polymorph formed at elevated temperatures is referred to as Polymorph 1, which may be obtained as an anhydrate.
  • Polymorph 1 may also be formed through crystallization via antisolvent addition. Polymorph 1 may be converted into at least four additional crystalline polymorphs formed at lower temperatures under various conditions.
  • Polymorphs 2-5 each have distinctive x-ray powder diffraction patterns and may be obtained readily through manipulation of Polymorph 1 under various conditions.
  • FIG. 15 shows an overlay plot of the x-ray powder diffraction patterns of Polymorphs 1-5.
  • Polymorph 1 exhibits additional x-ray powder diffraction peaks at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 17.70° and 17.86° (overlapping), 19.33° and 20.49°. Each of these peaks is present at a significant fraction of the intensity of the most intense peak of Polymorph 1. One or more additional peaks may be observed at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 9.19°, 10.27°, 11.71°, 13.55°, 15.62°, 21.90°, 26.76°, and 27.15°. These peaks are present at a considerably lower fraction of the intensity of the most intense peak of Polymorph 1.
  • Polymorph 1 may be converted into a second crystalline polymorph (Polymorph 2) characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 17.44° 2 ⁇ , as measured using Cu K ⁇ radiation.
  • Polymorph 1 may be converted to Polymorph 2 under thermal cycling conditions by transitioning between a temperature of 5°C and 50°C when slurried in various solvents.
  • Polymorph 2 may form at a phase transition temperature of about 40°C to about 60° and be obtained as an anhydrate.
  • temperature cycling to produce Polymorph 2 may be conducted in a 1 :2 ethanol/heptane (vol.wol.) slurry of Polymorph 1, as well as in other solvents producing a slurry of Polymorph 1.
  • Polymorph 2 may revert to Polymorph 1 upon heating above about 125°C.
  • Polymorph 2 exhibits additional x-ray powder diffraction peaks at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 8.72°, 17.99°, 18.46°, 18.83°, 19.51°, 19.98°, and 20.85°. Each of these peaks is present at a significant fraction of the intensity of the most intense peak of Polymorph 2. One or more additional peaks may be observed at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 11.51°, 13.24°, 14.03°, 15.50°, 15.86°, 16.18°, 27.05° and 27.83°. These peaks are present at a considerably lower fraction of the intensity of the most intense peak of Polymorph 2.
  • Polymorph 1 may be converted into a third crystalline polymorph (Polymorph 3) characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 18.57° 2 ⁇ as measured using Cu K ⁇ radiation.
  • Polymorph 1 may be converted to Polymorph 3 under thermal cycling conditions by transitioning between a temperature of 5°C and 50°C.
  • Polymorph 3 may form at a phase transition temperature of about 40°C or under and be obtained as an anhydrate.
  • temperature cycling to produce Polymorph 3 may be conducted in an acetonitrile slurry of Polymorph 1.
  • Polymorph 3 may revert to Polymorph 1 upon heating above about 125°C.
  • Polymorph 3 may be converted to Polymorph 2 upon heating above about 40°C and below about 125°C.
  • Polymorph 3 exhibits additional x-ray powder diffraction peaks at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 8.88°, 15.76°, 17.78°, 19.44°, 20.17°, and 20.61°. Each of these peaks is present at a significant fraction of the intensity of the most intense peak of Polymorph 3. One or more additional peaks may be observed at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 7.85°, 13.08°, 13.68°, 22.53°, 22.98°, 23.87°, 27.31°, and 27.91°. These peaks are present at a considerably lower fraction of the intensity of the most intense peak of Polymorph 3.
  • Polymorph 1 may be converted into a fourth crystalline polymorph (Polymorph 4) characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 17.62° 2 ⁇ , as measured using Cu K ⁇ radiation.
  • Polymorph 1 may be converted to Polymorph 4 by slow evaporatinn of a methanol solution or other solvents in which Polymorph 1 may be dissolved.
  • Polymorph 4 may be obtained as anhydrate.
  • Polymorph 4 may revert to Polymorph 1 upon heating above about 125°C.
  • Polymorph 4 may convert to Polymorph 2 upon heating above about 40°C and below about 125°C. Below about 40°C, Polymorph 4 may convert to Polymorph 3.
  • Polymorph 4 exhibits additional x-ray powder diffraction peaks at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 8.80°, 15.73°, 18.31°, 18.49°, 19.17°, 19.46°, 19.99°, 20.35°, and 20.72°. Each of these peaks is present at a significant fraction of the intensity of the most intense peak of Polymorph 4. One or more additional peaks may be observed at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 7.88°, 13.11°, 13.84°, 21.03°, 21.82°, 27.18°, and 27.86°. These peaks are present at a considerably lower fraction of the intensity of the most intense peak of Polymorph 4.
  • Polymorph 1 may be converted into a fifth crystalline polymorph (Polymorph 5) characterized by an x-ray powder diffraction pattern having a most-intense peak at approximately 16.91° 2 ⁇ , as measured using Cu K ⁇ radiation.
  • Polymorph 1 may be converted to Polymorph 5 under thermal cycling conditions by transitioning between a temperature of 5°C and 50°C.
  • Polymorph 5 may be obtained as an anhydrate.
  • temperature cycling to produce Polymorph 5 may be conducted in a 1 :3 THF/heptane (vol.:vol.) slurry or an MTBE slurry of Polymorph 1.
  • Polymorph 5 may revert to Polymorph 1 upon heating above about 125°C.
  • Polymorph 5 may convert to Polymorph 2 upon heating above about 40°C and below about 125°C. Below about 40°C, Polymorph 5 may convert to Polymorph 3.
  • Polymorph 5 exhibits additional x-ray powder diffraction peaks at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 8.43°, 17.26°, 17.54°, 18.04°, 18.52°, 19.20°, 19.86°, and 20.70°. Each of these peaks is present at a significant fraction of the intensity of the most intense peak of Polymorph 5. One or more additional peaks may be observed at the following approximate 2 ⁇ values, as measured using Cu K ⁇ radiation: 13.92°, 15.94°, 24.40°, 25.79°, 26.45°, and 27.16°. These peaks are present at a considerably lower fraction of the intensity of the most intense peak of Polymorph 5.
  • the 2 ⁇ peak positions described above are approximate and may vary to some degree depending on sample placement, instrument limitations, and other factors. Characterization of a sample as comprising a particular polymorph may be based upon mapping multiple x-ray powder diffraction peaks upon an unknown polymorphic form onto the known peak positions. The peak positions specified herein may vary by about 0.02° or less, or about 0.05° or less in some instances.
  • compositions may comprise any of Polymorphs 1-5. Suitable pharmaceutical compositions may comprise additional components, as described hereinafter. Particularly suitable pharmaceutical compositions may comprise Polymorph 3 or Polymorph 1, preferably Polymorph 3.
  • compositions comprising any compound herein, or a pharmaceutically acceptable form thereof.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the polymorphs described herein may be formulated using one or more pharmaceutically acceptable excipients (carriers) known to persons having ordinary skill in the art.
  • pharmaceutically acceptable excipient refers to substances or components that do not cause unacceptable losses of pharmacological activity or unacceptable adverse side effects when administered to a subject.
  • pharmaceutically acceptable excipients include, but are not limited to, solvents, dispersion media, coatings, antibacterial agents, antifungal agents, isotonic, and absorption delaying agents, provided that any of these agents do not produce significant side effects or are incompatible with the polymorphs.
  • Example excipients are described, for example, in Remington’s Pharmaceutical Sciences (A.R.
  • Such formulations may contain a therapeutically effective amount of one or more polymorphs, optionally as a salt, hydrate, and/or solvate, together with a suitable amount of excipient to provide a form for proper administration to a subject.
  • the pharmaceutical compositions may be present in solid or liquid form.
  • compositions of the present disclosure may be stable to specified storage conditions.
  • a “stable” composition refers to a composition having sufficient stability to allow storage at a convenient temperature, such as from about 0°C to about 60°C or about - 20°C to about 50°C, for a commercially reasonable period of time, such as at least about one day, at least about one week, at least about one month, at least about three months, at least about six months, at least about one year, or at least about two years.
  • compositions of the present disclosure may be tailored to suit a desired mode of administration, which may include, but are not limited to, parenteral, pulmonary, oral, topical, transdermal, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, ophthalmic, pulmonary, epidural, buccal, and rectal.
  • the pharmaceutical compositions may also be administered in combination with one or more additional agents or together with other biologically active or biologically inert agents.
  • Controlled-release (or sustained-release) pharmaceutical compositions may be formulated to extend the activity of mitofusin activation and reduce dosing frequency. Controlled-release pharmaceutical compositions may also be used to affect the time of onset of action or other characteristics, such as plasma levels of the mitofusin activator, and consequently affect the occurrence of side effects. Controlled-release pharmaceutical compositions may be designed to initially release an amount of one or more mitofusin activators that produces the desired therapeutic effect, and gradually and continually release other amounts of the mitofusin activator to maintain the level of therapeutic effect over an extended period.
  • the mitofusin activator may be released at a rate sufficient to replace the amount being metabolized or excreted from a subject.
  • the controlled-release may be stimulated by various inducers (e.g, change in pH, change in temperature, enzymes, water, or other physiological conditions or molecules).
  • compositions described herein may also be used in combination with other therapeutic modalities, as described further below.
  • therapies described herein one may also provide to the subject other therapies known to be efficacious for treatment of a disease, disorder, or condition being targeted by the mitofusin activator or a related disease, disorder, or condition.
  • the present disclosure features a method of treating diseases, disorders, or conditions, comprising administering to a subject in need thereof any compound described herein in a pharmaceutical composition.
  • the present disclosure features any compound described herein in a pharmaceutical composition for use for treating diseases, disorders, or conditions, comprising administering to a subject in need thereof.
  • the present disclosure features use of any compound described herein in a pharmaceutical composition in the manufacture of a medicament for treating diseases, disorders, or conditions, composing administering to a subject in need thereof.
  • the present disclosure features a method of activating mitofusin in a subject, comprising administering the compound or the pharmaceutical composition of any one of the preceding claims.
  • the present disclosure features any compound described herein in a pharmaceutical composition for use in activating mitofusin in a subject.
  • the present disclosure features use of the any compound described herein in a pharmaceutical composition in the manufacture of a medicament for activating mitofusin in a subject.
  • a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof can be used to treat or prevent a disease, disorder, or condition in a subject.
  • a therapeutically effective amount of the compound or the pharmaceutical composition described herein is administered to the subject.
  • the disease, disorder, or condition is associated with mitochondria.
  • the subject is human.
  • Mitofusin activators of the present disclosure may stimulate mitochondrial fusion, increase mitochondrial fitness, and enhance mitochondrial subcellular transport. Accordingly, in another aspect of the present disclosure, any one or a combination of mitofusin activators of the present disclosure or a pharmaceutically acceptable salt thereof may be administered in a therapeutically effective amount to a subject having or suspected of having a mitochondria- associated disease, disorder or condition.
  • the subject may be a human or other mammal having or suspected of having a mitochondna-associated disease, disorder, or condition.
  • Any of the crystalline polymorphs of the present disclosure may be administered to the subj ect in a suitable form.
  • the mitofusin activator is present as a cry stalline polymorph or a dissolved form thereof, particularly Polymorph 3, as specified above.
  • the mitochondria-associated disease, disorder, or condition may be a pheripheral nervous system (PNS) or central nervous system (CNS) genetic or non-genetic disorder, physical damage, and/or chemical injury.
  • the PNS or CNS disorder may be selected from any one or a combination of: a chronic neurodegenerative condition wherein mitochondrial fusion, fitness, or trafficking are impaired; a disease or disorder associated with mitofusin- 1 (MFN1) or mitofusin-2 (MFN2) dysfunction; a disease associated with mitochondrial fragmentation, dysfunction, or dysmotility; a degenerative neuromuscular condition such as Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, hereditary motor and sensory neuropathy, autism, autosomal dominant optic atrophy (ADOA), muscular dystrophy, Lou Gehrig's disease, cancer,
  • ALS amyotrophic lateral sclerosis
  • ADOA autosomal dominant optic atrophy
  • Other mitochondria-associated diseases, disorders, or conditions that may be treated with the compositions disclosed herein mlcude are not limited to, Alzheimer's disease, ALS, Alexander disease, Alpers' disease, Alpers-Huttenlocher syndrome, alpha-methylacyl- CoA racemase deficiency, Andermann syndrome, Arts syndrome, ataxia neuropathy spectrum, ataxia (e.g., with oculomotor apraxia, autosomal dominant cerebellar ataxia, deafness, and narcolepsy), autosomal recessive spastic ataxia of Charlevoix-Saguenay, Batten disease, beta- propeller protein-associated neurodegeneration, cerebro-oculo-facio-skeletal syndrome (COFS), corticobasal degeneration, CLN1 disease, CLN10 disease, CLN2 disease, CLN3 disease, CLN4 disease, CLN6 disease, CLN7 disease, CLN8 disease, cognitive dysfunction, congenital insensitivity to pain
  • mitochrondria-associated diseases, disorders, or conditions that may be treated with the compositions disclosed herein include abulia; agraphia; alcoholism; alexia; alien hand syndrome; Allan-Hemdon-Dudley syndrome; alternating hemiplegia of childhood; Alzheimer's disease; amaurosis fugax; amnesia; ALS; aneurysm; angelman syndrome; anosognosia; aphasia; apraxia; arachnoiditis; Amold-Chiari malformation; asomatognosia; Asperger syndrome; ataxia; attention deficit hyperactivity disorder; atr-16 syndrome; auditory processing disorder; autism spectrum; Behcets disease; bipolar disorder; Bell's palsy; brachial plexus injury; brain damage; brain injury; brain tumor; Brody myopathy; Canavan disease; capgras delusion; carpal tunnel syndrome; causalgia; central pain syndrome; central pontine myelin
  • treating a state, disease, disorder, or condition includes preventing or delaying the appearance of clinical symptoms in a mammal that may be afflicted with or predisposed to the state, disease, disorder, or condition but does not yet experience or display clinical or subclinical symptoms thereof. Treating can also include inhibiting the state, disease, disorder, or condition (e.g., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof). Furthermore, treating can include relieving the disease (e.g., causing regression of the state, disease, disorder, or condition or at least one of its clinical or subclinical symptoms). A benefit to a subject to be treated can be either statistically significant or at least perceptible to the subject or to a physician.
  • a mitochondria-associated disease, disorder, or condition may be a disease primarily caused by or secondarily associated with mitochondrial dysfunction, fragmentation, or loss-of- fusion, or associated with dysfunction in MFN1 or MFN2 catalytic activity or conformational unfolding.
  • Mitochondrial dysfunction may be caused by genetic mutations of mitofusins or other (nuclear or mitochondrial encoded) genes, or may be caused by physical, chemical, or environmental injury to the CNS or PNS.
  • cancer chemotherapy-induced sensory and motor neuropathies may be prevented or treated with the compositions of the present disclosure.
  • Chemotherapy- induced peripheral neuropathy is one of the most common complications of cancer chemotherapy, affecting 20% of all patients and almost 100% of patients receiving high doses of chemotherapeutic agents. Dose-dependent neurotoxicity of motor and sensory neurons can lead to chronic pain, hypersensitivity to hot, cold, and mechanical stimuli, and/or impaired neuromuscular control.
  • the most common chemotherapeutic agents linked to CIPN are platinum, vinca alkaloids, taxanes, epothilones, and the targeted proteasome inhibitor, bortezomib.
  • CIPN most commonly affects peripheral sensory neurons whose cell bodies are located in dorsal root ganglia lacking the blood-brain barrier that protects other components of the central and peripheral nervous system. Unprotected dorsal root ganglion neurons are more sensitive to neuronal hyperexcitability and innate immune system activation evoked by circulating cytotoxic chemotherapeutic agents. CIPN affects quality of life, and is potentially disabling, because it provokes chronic neuropathic pain that, like other causes of neuralgia (e.g., post herpetic neuralgia, diabetic mononeuropathy), is refractory to analgesic therapy.
  • neuralgia e.g., post herpetic neuralgia, diabetic mononeuropathy
  • CIPN Motor nerve involvement commonly manifests as loss of fine motor function with deterioration in hand writing, difficulty in buttoning clothes or sewing, and sometimes upper and lower extremity weakness or loss of endurance.
  • CIPN typically manifests within weeks of chemotherapy and in many cases improves after chemotherapy treatment ends, although residual pain, sensory, or motor defects are observed in one-third to one-half of affected patients.
  • CIPN-limited chemotherapy dosing can lead to delays, reduction, or interruption of cancer treatment, thus shortening survival.
  • Mitochondrial dysfunction and oxidative stress are implicated in CIPN because of observed ultrastructural morphological abnormalities, impaired mitochondria DNA transcription and replication, induction of mitochondrial apoptosis pathways, and reduction of experimental CIPN signs by anticipatory mitochondrial protection.
  • Mitofusin activators may enhance overall mitochondrial function in damaged neurons, increase mitochondrial transport to areas of neuronal damage, and accelerate in vitro neuron repair/regeneration after chemotherapy-induced damage. For this reason, it is believed that mitofusin activators may reduce neuronal injury conferred by chemotherapeutic agents in CIPN and accelerate regeneration/repair of nerves damaged by chemotherapeutic anticancer agents.
  • the present disclosure provides for compositions and methods to treat cancer chemotherapy induced nerve injury and neuropathy.
  • injury in the CNS or PNS may be treated with the compositions of the present disclosure.
  • the CNS includes the brain and the spinal cord and the PNS is composed of cranial, spinal, and autonomic nerves that connect to the CNS.
  • Damage to the nervous system caused by mechanical, thermal, chemical, or ischemic factors may impair various nervous system functions such as memory, cognition, language, and voluntary movement. Most often, this is through accidental crush or transection of nerve tracts, or as an unintended consequence of medical interventions, that interrupt normal communications between nerve cell bodies and their targets. Other types of injuries may include disruption of the interrelations between neurons and their supporting cells or the destruction of the blood-brain barrier.
  • Mitofusin activators may rapidly reverse mitochondrial dysmotility in neurons from mice or patients with various genetic or chemotherapeutic neurodegenerative diseases, in axons injured by chemotherapeutic agents, and in axons severed by physical injury. For this reason, mitofusin activators may enhance regeneration/repair of physically damaged nerves, as in vehicular and sports injuries, penetration trauma from military or criminal actions, and iatrogenic injury during invasive medical procedures. As such, the present disclosure provides for compositions and methods to treat physical nerve injury.
  • Mitochondrial motility is also implicated in neuropathy and traumatic crush or severance nerve injuries. After nerve laceration or crush injury, nerves will either regenerate and restore neuromuscular function or fail to regenerate such that neuromuscular function in permanently impaired. Mitofusin activators may increase mitochondrial trafficking, thereby enabling a nerve to regenerate after traumatic injuries.
  • the amount of a mitofusin activator and excipient to produce a pharmaceutical composition in a given dosage form may vary depending upon the subject being treated, the condition being treated, and the particular mode of administration. It will be appreciated that the unit content of mitofusin activator contained in an individual dose of a given dosage form need not in itself constitute a therapeutically effective amount, as the necessary therapeutically effective amount could be reached by administration of a number of individual doses, or the therapeutic effect may be cumulative over time.
  • Dosing of the mitofusin activators of the present disclosure may occur as a single event or over a time course of treatment.
  • a mitofusin activator may be administered daily, weekly, bi-weekly, or monthly.
  • the time course of treatment may be at least several days, with dosing taking place at least once a day or continuously.
  • Certain conditions could extend treatment from several days to several weeks. For example, treatment could extend over one week, two weeks, or three weeks.
  • Treatment could extend from several weeks to several months or even years.
  • Toxicity and therapeutic efficacy of the compositions described herein may be determined by standard pharmaceutical procedures in cell cultures or experimental animals for determining the LDso (the dose lethal to 50% of the population) and the ED50, (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index that may be expressed as the ratio LD50/ED50, where larger therapeutic indices are generally understood in the art to be optimal.
  • the therapeutic index may be about 30 or greater.
  • treat or “treatment”, unless otherwise indicated by context, refer to any administration of a therapeutic molecule (e.g., any compound described herein) that partially or completely alleviates, ameliorates, relieves, inhibits, reduces severity of and/or reduces incidence of one or more symptoms or features of a particular disease, disorder, and/or condition.
  • a therapeutic molecule e.g., any compound described herein
  • the term “preventing,” “prevent,” or “protecting against” describes delaying onset or slowing progression of a disease, condition or disorder.
  • the term “subject” includes human and non-human animals, as well as cell lines, cell cultures, tissues, and organs.
  • the subject is a mammal.
  • the mammal can be e.g. , a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig.
  • the subject can also be a bird or fowl.
  • the subject is a human.
  • the term “subject in need thereof’ refers to a subject having a disease or having an increased risk of developing the disease.
  • a subject in need thereof can be one who has been previously diagnosed or identified as having a disease or disorder disclosed herein.
  • a subject in need thereof can also be one who is suffering from a disease or disorder disclosed herein.
  • a subject in need thereof can be one who has an increased risk of developing such disease or disorder relative to the population at large (i.e., a subject who is predisposed to developing such disorder relative to the population at large).
  • a subject in need thereof can have a refractory or resistant a disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment).
  • the subject may be resistant at start of treatment or may become resistant dunng treatment.
  • the subject in need thereof received and failed all known effective therapies for a disease or disorder disclosed herein.
  • the subject in need thereof received at least one prior therapy.
  • terapéuticaally effective amount refers to an amount of a conjugate effective to treat or prevent a disease or disorder in a subject (e.g., as described herein).
  • the term “pharmaceutical composition” refers to a composition in which an active agent is formulated together with one or more pharmaceutically acceptable carriers.
  • the active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population.
  • a pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream, or foam; sublingually; ocularly; transdermally; or nasally, pulmonary, and to other mucosal surfaces.
  • oral administration for example, drenches (aqueous or non-aqueous solutions
  • administration typically refers to the administration of a composition to a subject or system to achieve delivery of an agent that is, or is included in, the composition.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration.
  • parenteral e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration.
  • administration may be ocular, oral, parenteral, topical, etc.
  • administration is parenteral (e.g., intravenous administration).
  • intravenous administration is intravenous infusion.
  • administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g. intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc.
  • bronchial e.g., by bronchial instillation
  • buccal which may be or comprise, for example, one or more of topical to the dermis
  • the term “pharmaceutically acceptable salt” refers to organic or inorganic salts of a polymorph of the present disclosure that have specified toxicity and/or biodistribution properties. Suitable salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, and/or pamoate (i
  • the pharmaceutically acceptable salt may balance charge on the parent polymorph by being present as a counterion. More than one counterion may be present. When multiple counterions are present, the polymorphs may be present as a mixed pharmaceutically acceptable salt.
  • Pharmaceutically acceptable salts, solvates, and/or hydrates of any of Polymorphs 1-5 may be present in the pharmaceutical compositions of the present disclosure.
  • pharmaceutically acceptable solvate refers to an association between one or more solvent molecules and a polymorph of the present disclosure or a salt thereof, wherein the solvate has specified toxicity and/or biodistribution properties.
  • solvents that may form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and/or ethanolamine.
  • pharmaceutically acceptable hydrate refers to a polymorph of the present disclosure or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent mtermolecular forces, wherein the hydrate has specified toxicity and/or biodistribution properties.
  • the polymorphs of the present disclosure are substantially non-solvated and substantially non-hydrated when present in the pharmaceutical compositions described herein.
  • TGA Thermogravimetric analysis
  • DSC Differential scanning calorimetry
  • FIG. 1 shows an illustrative x-ray powder diffraction pattern of as-produced N-(trans-4- hydroxycyclohexyl)-5-phenylpentanamide.
  • the as-produced polymorph form of N-(trans-4- hydroxycyclohexyl)-5-phenylpentanamide is designated as Polymorph 1 herein. As shown, this polymorph may be characterized by its most-intense peak at approximately 18.43° 2 ⁇ . Table 3 shows additional peak positions in the x-ray powder diffraction pattern of Polymorph 1 and their relative intensity compared to the most intense peak.
  • FIG. 2 shows an illustrative polarized light microscopy image of as-produced N -(trans- 4-hydroxycyclohexyl)-5-phenylpentanamide (Polymorph 1).
  • Polymorph 1 exhibited a rod-like morphology.
  • TGA and DSC (not shown) showed a single thermal event at approximately 132°C, indicative of melting, and afforded negligible weight loss, leading to an anhydrate designation for this polymorphic form. No change was observed in the x-ray powder diffraction pattern upon heating to 125°C.
  • Polymorph 1 was also obtained by layering an anti-solvent onto a solution of N -(trans--4-hydroxycyclohexyl)-5-phenylpentanamide and allowing crystallization to take place.
  • FIG. 4 shows an illustrative polarized light microscopy image of Polymorph 2 of N-(trans--4-hydroxycyclohexyl)-5-phenylpentanamide. As shown, Polymorph 2 had a small, needle-like morphology.
  • FIG. 5 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 2 of N-(trans-4- hydroxycyclohexyl)-5-phenylpentanamide. The small endotherm at 123.4°C and exotherm at 128.8°C are believed to result from concurrent melting and recrystallization of Polymorph 2 to reform Polymorph 1.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • FIG. 7 shows an illustrative polarized light microscopy image of Polymorph 3 of N-(trans-4-hydroxycyclohexyl)-5-phenylpentanamide. As shown, Polymorph 3 consisted of small agglomerated particles.
  • FIG. 8 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 3 of N-(trans-4- hydroxycyclohexyl)-5-phenylpentanamide. The endothermic events in the TGA/DSC plot are believed to result from reformation of Polymorph 1 at elevated temperatures. Otherwise, based upon negligible weight loss, the thermal data is consistent with designation of Polymorph 3 as an anhydrate. Upon heating Polymorph 3 to 125°C, Polymorph 1 reformed, as evidenced by reversion of the x-ray powder diffraction pattern to that shown in FIG. 1.
  • FIG. 10 shows an illustrative polarized light microscopy image of Polymorph 4 of N-(trans-4-hydroxycyclohexyl)-5-phenylpentanamide. As shown, Polymorph 4 consisted of small needle-like particles.
  • FIG. 11 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 4 of N-(trans-4- hydroxycyclohexyl)-5-phenylpentanamide. The endothermic events in the TGA/DSC plot are believed to result from reformation of Polymorph 1 at elevated temperature. Otherwise, based upon negligible weight loss, the thermal data is consistent with designation of Polymorph 4 as an anhydrate. Upon heating Polymorph 4 to 125°C, Polymorph 1 reformed, as evidenced by reversion of the x-ray powder diffraction pattern to that shown in FIG. 1.
  • FIG. 12 shows an illustrative x-ray powder diffraction pattern of Polymorph 5 of N-(trans-4-hydroxycyclohexyl)-5- phenylpentanamide, characterized by its most-intense peak at approximately 16.91° 2Q.
  • Table 7 shows additional peak positions in the x-ray powder diffraction pattern of Polymorph 5 and their relative intensity compared to the most intense peak.
  • FIG. 13 shows an illustrative polarized light microscopy image of Polymorph 5 of N-(trans-4-hydroxycyclohexyl)-5-phenylpentanamide. As shown, Polymorph 5 consisted of small needle-like crystals.
  • FIG. 14 shows an illustrative thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) plot of Polymorph 5 of N- N-(trans-4 hydroxycyclohexyl)-5-phenylpentanamide. The endothermic events in the TGA/DSC plot are believed to result from reformation of Polymorph 1 at elevated temperature. Otherwise, based upon negligible weight loss, the thermal data is consistent with designation of Polymorph 5 as an anhydrate.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • a saturated stock solution of Polymorph 1 in methyl isobutyl ketone was prepared, and separate suspensions containing an equivalent amount of Polymorph 2 or Polymorph 3 were prepared from the Polymorph 1 saturated stock solution.
  • the suspensions were maintained at 30°C, 40°C or 50°C for one or three days, and the x-ray powder diffraction patterns of the residue were checked at these times.
  • Polymorph 3 formed at 30°C and 40°C from each suspension.
  • Polymorph 2 formed at 50°C from each suspension.
  • Polymorph 1 is the predominant polymorph.
  • Solubility Testing was conducted by placing 2 mg of a polymorph sample into a 3 mL glass vial, and solvent was added stepwise (50 ⁇ L, 50 ⁇ L, 200 ⁇ L, 700 ⁇ L) until the solids dissolved or a total volume of 1 mL was reached. Solubility was estimated visually based upon the amounts of polymorph sample and solvent added. Solubility was determined at room temperature. Table 8 summarizes the approximate solubility of Polymorph 1 in various solvents at room temperature.
  • Polymorph 3 was the most low-temperature stable polymorph, more detailed solubility testing data was collected for this polymorph in a range of vehicles potentially applicable for biological testing.
  • Table 9 summarizes the approximate solubility of Polymorph 3 in various vehicles at room temperature. The approximate solubility was determined in a similar manner to that described above for Polymorph 1.
  • Aqueous solubility of Polymorph 3 was determined by adding excess Polymorph 3 to a glass HPLC vial and adding a known quantity of water to make a slurry. After stirring at room temperature for 24 hours, the remaining solid was removed through centrifugation. The supernatant was passed through a 0.2 ⁇ m filter and diluted for HPLC analysis. The saturation concentration of Polymorph 3 in water was found to be 0.155 mg/mL. No phase conversion was found for the residue solid.
  • Table 10 Entries marked with an asterisk were tested for compatibility with SGF (NaCl), FaSSIF (phosphate), and FeSSIF (acetate) biological media. All except 20% TPGS in Capmul were compatible with these biological media when mixed in a 1:5 vol.wol. ratio.
  • Table 11 summarizes the saturation solubility of Polymorph 3 when mixed with 1:5 vol.wol. vehicle:biologically relevant medium.
  • the phrase “at least one of’ preceding a series of items, with the terms “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item).
  • the phrase “at least one of’ allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items.
  • the phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente divulgation concerne des polymorphes cristallins de N-(trans-4-hydroxycyclohexyl)-6-pheéylhexanamide, ainsi que des compositions pharmaceutiques qui peuvent être préparées à partir des polymorphes. La présente divulgation concerne également des utilisations des polymorphes cristallins, par exemple, dans le traitement ou la prévention d'une maladie, d'un trouble ou d'un état pathologique.
PCT/US2022/021321 2021-03-22 2022-03-22 Formes polymorphes de n-(trans-4-hydroxycyclohexyl)-6-phénylhexanamide WO2022204125A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163164286P 2021-03-22 2021-03-22
US202163164266P 2021-03-22 2021-03-22
US63/164,286 2021-03-22
US63/164,266 2021-03-22

Publications (1)

Publication Number Publication Date
WO2022204125A1 true WO2022204125A1 (fr) 2022-09-29

Family

ID=81449163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/021321 WO2022204125A1 (fr) 2021-03-22 2022-03-22 Formes polymorphes de n-(trans-4-hydroxycyclohexyl)-6-phénylhexanamide

Country Status (1)

Country Link
WO (1) WO2022204125A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345668A1 (en) 2019-01-28 2020-11-05 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
US20200345669A1 (en) 2019-01-28 2020-11-05 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345668A1 (en) 2019-01-28 2020-11-05 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
US20200345669A1 (en) 2019-01-28 2020-11-05 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 2005
DANG XIAWEI ET AL: "Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 13, 9 July 2020 (2020-07-09), US, pages 7033 - 7051, XP055933541, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c00366 *

Similar Documents

Publication Publication Date Title
US11000534B1 (en) Deuterated derivatives of psilocybin and uses thereof
TWI784662B (zh) 苯甲酸鈉之同素異形體形式及其用途
US11083699B2 (en) Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
US10570157B2 (en) Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors
US20110301235A1 (en) Organoselenium compounds and uses thereof
US10098861B1 (en) Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
TWI819502B (zh) 一種三伸乙基四胺四氫氯化物及其製備方法與組合物
US8153672B2 (en) Polymorphic forms of deferasirox (ICL670A)
US20190274984A1 (en) Polymorphic forms of sodium benzoate and uses thereof
WO2022204125A1 (fr) Formes polymorphes de n-(trans-4-hydroxycyclohexyl)-6-phénylhexanamide
AU2013334860B2 (en) Compositions and methods for treating or preventing diseases or disorders associated with misregulated elF4E
EP3939978A1 (fr) Forme cristalline d'un inhibiteur de phosphodiestérase, son procédé de préparation et son utilisation
WO2023196340A1 (fr) Activateurs de mitofusine comportant un groupe carbonyle lié endocyclique et leurs méthodes d'utilisation
US6583138B1 (en) Heterocyclic-ring condensed benzothiazine compound
US20240199534A1 (en) Cyclopropane analogues of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide and related compounds
JP3089040B2 (ja) 脳神経変性性疾患治療剤
CN109535150B (zh) 苯乙酸替扎尼定晶型a及其制备方法和用途
CN109535152B (zh) 硝酸替扎尼定晶型a及其制备方法和用途
CN117143027A (zh) 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途
WO2023043899A1 (fr) Dérivés deutérés de salvinorine a et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22720097

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22720097

Country of ref document: EP

Kind code of ref document: A1